A look at the financing, M&A and alliance activity in July–September 2018
• By Amanda Micklus and Maureen Riordan
Third quarter device financing totaled $2.6 billion, a 24% decrease from the $3.4 billion brought in during Q2. The change partially stems from a sharp decline in debt financing. During the third quarter, debt raises brought in $258 million, just 10% of the Q3 total, while in the previous quarter, aggregate debt (at $947 million) represented 28% of the financing total.
Device fundraising in the third quarter totaled $2.6 billion, a 24% decrease from Q2's $3.4 billion. Q3 M&A activity reached $5.6 billion, also a decline from the previous quarter. Q3 diagnostics financings totaled $900 million and M&As $532 million, both lower than Q2.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.